NCI SBIR PROGRAM OVERVIEW

Size: px

Start display at page:

Download "NCI SBIR PROGRAM OVERVIEW"

Madeline Dalton
5 years ago
Views:

1 NCI SBIR PROGRAM OVERVIEW DEEPA NARAYANAN Program Director NCI SBIR Development Center Jefferson Labs Workshop, Tech Transfer 2018 January 11,2018 1

2 Congressionally Mandated Small Business Innovation Research (SBIR) Set-aside program for small business concerns to engage in Federal R&D with the potential for commercialization Federal agencies with an extramural R&D budget > $100M Set Aside FY11 FY17 2.5% 3.2% Small Business Technology Transfer (STTR) Set-aside program to facilitate cooperative R&D between small business concerns and U.S. research institutions with the potential for commercialization Federal agencies with an extramural R&D budget > $1B 0.3% 0.45% ~$980M in FY17 at NIH ~$159M in FY17 at NCI [$148M Appropriation + $11M Cancer Moonshot Funding]

3 NIH has 27 Institutes and Centers 23 separate SBIR/STTR Programs The Office of the Director (OD) National Institute on Aging (NIA) National Institute on Alcohol Abuse & Alcoholism (NIAAA) National Institute of Allergy & Infectious Diseases (NIAID) National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) National Cancer Institute (NCI) National Institute of Child Health & Human Development (NICHD) National Institute on Deafness & Other Communication Disorders (NIDCD) National Institute of Dental and Craniofacial Research (NIDCR) National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) National Institute on Drug Abuse (NIDA) National Institute of Environmental Health Sciences (NIEHS) National Eye Institute (NEI) National Institute of General Medical Sciences (NIGMS) National Heart Lung & Blood Institute (NHLBI) National Human Genome Research Institute (NHGRI) National Institute of Mental Health (NIMH) National Institute of Neurological Disorders & Stroke (NINDS) National Institute of Nursing Research (NINR) National Institute on Minority Health & Health Disparities (NIMHD) National Center for Complementary & Integrative Health (NCCIH) Fogarty International Center (FIC) National Center for Advancing Translational Sciences (NCATS) National Library of Medicine (NLM) National Institute of Biomedical Imaging & Bioengineering (NIBIB) NIH Clinical Center (CC) Center for Information Technology (CIT) Center for Scientific Review (CSR) No funding authority 3

SUCCESS STORY: TOMOTHERAPY Founded in 1997 (Middleton, WI) Key Technology: TomoTherapy radiation therapy platform TomoTherapy radiation therapy system allows for customized treatment delivery based

4 SUCCESS STORY: TOMOTHERAPY Founded in 1997 (Middleton, WI) Key Technology: TomoTherapy radiation therapy platform TomoTherapy radiation therapy system allows for customized treatment delivery based on verifying the patient anatomy each day using additional radiation technology built into a CT scanner gantry. Regular R01 (1988) advanced the concept but SBIRs proved key aspects of the technology Rock Mackie Co-founder and Chairman Tomotherapy KEY MILESTONES Received 3 Awards from NCI SBIR ( ) Received 510(k) clearance (2002) IPO 2007 Acquired by Accuray - $277 million + stock (2011) #FueledbyNCISBIR 4

5 THREE-PHASE PROGRAM FAST-TRACK (PH I & II) PHASE I PHASE II NCI SBIR PHASE IIB BRIDGE AWARD CROSSING THE VALLEY OF DEATH PHASE III Proof-of- Concept Up to $300,000 over 6 to 12 months Research & Development Commercialization plan required Up to $2M over 2 years Technology validation & clinical translation Follow-on funding for SBIR Phase II awardees from any federal agencies Expectation that applicants will secure substantial 3 rd party investor funds $3M over 3 years Phase I Standard Award Commercialization stage Use of non- SBIR/STTR funds Hard Cap Waiver Cap (IC Specific) $150k $225k NCI: $300k Phase II $1.0M $1.5M NCI: $2.0M5

S.- owned by individuals and independently operated OR 50% owned and controlled by another (one) business concern that is

6 ELIGIBILITY Applicant must be a Small Business Concern (SBC) Organized for-profit U.S. business 500 or fewer employees, including affiliates Award ALWAYS made to small business 50% U.S.- owned by individuals and independently operated OR 50% owned and controlled by another (one) business concern that is 50% owned and controlled by one or more individuals OR (SBIR ONLY) 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these 6

7 CRITICAL DIFFERENCES SBIR Permits research institution partners (e.g., universities) STTR Requires research institution partners (e.g., universities) Small business concern may outsource ~33% of Phase I activities and 50% of Phase II activities ELIGIBILITY: The PD/PI s primary employment (i.e., >50%) MUST be with the SBC for the duration of the project period Minimum 40% of the work should be conducted by the small business concern (for profit), and minimum of 30% by a U.S. research institution (non-profit) ELIGIBILITY:IP Agreement providing necessary IP rights to the SBC in order to carry out follow-on R&D and commercialization PI primary employment not stipulated (min.10% effort to project) 7

8 FY 16 SUCCESS RATES NIH SBIR/STTR Phase # of Applications Reviewed # of Applications Awarded Success Rate 31.4% SBIR Phase I 4, % Phase II 1, % 25.0% STTR Phase I 1, % Phase II % 12.6% 14.2% FY TOTAL 7,522 1, % Phase I Phase II SBIR STTR Success Rates Posted Online: 8

9 FY 16 SUCCESS RATES NCI SBIR/STTR SBIR Phase # of Applications Reviewed # of Applications Awarded Success Rate Phase I % Phase II % 10% 16% 15% 18% STTR Phase I % Phase II % FY TOTAL % Phase I SBIR STTR Phase II 9

10 NCI SBIR Development Center Michael Weingarten, MA Director NCI SBIR Development Center Let s discuss your project! Send Specific Aims to ncisbir@mail.nih.gov Greg Evans, PhD Lead Program Director Cancer Biology, E-Health, Epidemiology, Research Tools Patricia Weber, DrPH Program Director Digital Health, Therapeutics, Biologics, FRAC Workshop Deepa Narayanan, MS Program Director Imaging, Clinical Trials, Radiation Therapy, Investor Initiatives, FRAC Workshop Ming Zhao, PhD Program Director Cancer Diagnostics & Therapeutics, Cancer Control & Prevention, Molecular Imaging, Bioinformatics, Stem Cells Christie Canaria, PhD Program Director Cancer/Biological Imaging, Research Tools, Devices, I-Corps at NIH, Scientific Communications Kory Hallett, PhD Program Manager Monoclonal Antibodies, Immunotherapy, Biologics, and Program Analysis Andrew J. Kurtz, PhD Lead Program Director Biologics, Small Molecules, Nanotherapeutics, Molecular Diagnostics, Bridge Award Jian Lou, PhD Program Director In-Vitro Diagnostics, Theranostics, early-stage drug development, Bioinformatics, Investor Initiatives Todd Haim, PhD Program Director Small Molecules, Biologics, Immunotherapy, Theranostics, Investor Initiatives, FRAC Workshop Amir Rahbar, PhD, MBA Program Director In-Vitro Diagnostics, Biologics, Therapeutics, Proteomics Jonathan Franca-Koh, PhD, MBA Program Director Cancer Biology, Biologics, Small Molecules, Cell Based Therapies Ashim Subedee, PhD Program Director Cancer Therapeutics and Diagnostics, Imaging, Cancer Prevention and Control, Digital Health, Investor Initiatives

11 Development Center: 5 CORE ACTIVITIES CENTRAL OVERSIGHT Administer all 400+ SBIR/STTR awards at the NCI GUIDANCE Help applicants prepare for application, resubmission, and discuss funding options OUTREACH Attend conferences and workshops & visit state-based organizations and universities to raise awareness of the program NETWORKING FUNDING Maintain a network of investors, and facilitate connections between NCI SBIR portfolio companies and potential investors/strategic partners Seed emerging technology areas by developing targeted funding opportunities either as grants or contracts 11

12 NCI SBIR/STTR Funding Major Portfolio Areas (FY2016) GRANTS & CONTRACTS Contracts 25% Grants 75% ~400 Total Ongoing Projects ~90 Total Contracts totaling $34MM 12

13 GRANT vs. CONTRACT Scope of the proposal Peer Review Locus Questions during solicitation period? GRANT Investigator-defined within the mission of NIH NIH Center for Scientific Review (CSR) May speak with any Program Officer CONTRACT Defined by the NIH (focused) NCI DEA (target 50% business reviewers) MUST contact the contracting officer Receipt Dates 3 times/year for Omnibus Only ONCE per year Set-aside of funds for particular areas? Basis for Award Reporting NO Based on score during peer review One final report (Phase I); Annual reports (Phase II) YES If proposal scores well during peer review, must then negotiate to finalize deliverables with NIH Kick-off presentation, quarterly progress & final reports 13

14 Investigator-Initiated Grants Omnibus Solicitations (Phase I, Phase II, FastTrack) PA (SBIR) and PA (STTR) We encourage applications for any topic within the NIH mission Due September 5, January 5, April 5 14

15 CONTRACT TOPICS Dollars in Thousands Contracts in NCI SBIR Portfolio NCI scientific & technology priorities CONTRACT TOPICS Areas of interest to commercial sector 140, , ,000 80,000 33% ($38M) 35% ($39M) 31% ($37M) 24% ($29M) 25% ($34M) 60,000 40,000 Topics are in NCI priority areas with strong potential for commercial success 20,000 0 FY 2012 FY 2013 FY 2014 FY 2015 FY 2016 Grants R&D Contracts 15

16 R&D Contract Funding Opportunity HHS Small Business Innovation Research (SBIR) Program Contract Solicitation ONE application receipt date per year: Published July of each year Receipt Date: October 2018 More info about NCI s topic areas:

17 FY2018 NCI Contract NCI Topics Contract for FY16 Opportunities Targeted Therapy for Cancer- and Cancer Therapy-Related Cachexia 371. Drugs to Exploit the Immune Response Generated by Radiation Therapy 372. Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics 373. Tools and Technologies for Monitoring RNA Modifications 374. Novel Approaches for Local Delivery of Chemopreventive Agents 375. Diagnostic Imaging for Cancer Immunotherapies 376. Imaging-Based Tools for Longitudinal and Multi-Dimensional Mapping of the Tumor and its Microenvironment 377. Bridging the Guideline Implementation Gap: Clinical Decision-Support to Improve Cancer Symptom Management 378. Mobile Application for Surveillance of Post-Radiation Therapy Health-Related Quality-of-Life 379. Software Enabling Data Integration from Wearable Sensors to Generate Novel Analytics for Cancer Patients 380. Computer Aided Decision Support for Radiation Oncology 381. Development of Artificial Intelligence (AI) Tools to Understand and Duplicate Experts' Radiation Therapy Planning for Prostate Cancer

18 NCI SBIR Phase IIB Bridge Awards FAST-TRACK (PH I & II) Non-SBIR/STTR Funds PHASE I PHASE II NCI SBIR PHASE IIB BRIDGE AWARD CROSSING THE VALLEY OF DEATH PHASE III Commercialization Provides up to $1M per year for up to 3 years Technology validation and clinical translation Open to any NIH-funded Phase II awardees with projects relevant to NCI mission Accelerates commercialization by incentivizing partnerships with third-party investors & strategic partners earlier in the development process Competitive preference and funding priority to applicants that can raise substantial third-party funds (i.e., 1:1 match) 18

19 18 Bridge Awards 21 Bridge Awards FY2009 FY2016 FY2009 FY2014 $15,000,000 = NCI award = Third-Party Investments $10,000,000 $3M $5,000,000 $0 NCI Total $42.8 M Third-Party Investments $86.3 M Leverage > 2 to 1 40% Venture Capital 35% Strategic Partners 25% Angels & Individuals 19

20 Is SBIR/STTR appropriate? Example: Start-up company, too early for private investment Seeking funding to produce feasibility data (Phase 1) Seeking funding for development (Phase 2) Aruna Gambhir, MS, MBA CEO and Co-Founder CellSight Technologies Investors want to see that a technology works. SBIR funding has been critical to our company to show that our technology works. 20

21 FOA & RECEIPT DATES TITLE FOA RECEIPT DATES Omnibus Solicitation PA for SBIR PA for STTR (FAST TRACK AVAILABLE) September 5; January 5; April 5 SBIR Technology Transfer PA Phase IIB Bridge Award RFA-CA July-August Contract Solicitation Program Solicitation PHS Release: July-August Receipt: October - November 21

22 Pre-application communication The program office is here to help Contact an appropriate NIH Program Director in advance (at least 1 month before due date!), to discuss your specific aims and receive feedback Standard dates: September 5 th, January 5 th, April 5th Do your homework on NIH funded applications NIH RePORTER Exploit your strengths, acknowledge and mitigate weaknesses

23 Search Previous Awards Search Previous Awards

24 SF424 Application Guide updated periodically SF424 Application Guide NEW VERSION New web-based guide

25 APPLICATION ACADEMIC GRANT SBIR/STTR GRANT Expertise/Team (Discovery Research) Expertise/Team Phase I: Research and Development Phase II: Commercial Development Approach (Appropriate for discovery) Environment Approach (Product Development) Environment SCIENCE PRODUCT Product (optional) Significance (Knowledge increase) Science (MANDATORY) Significance (Changing a paradigm) Innovation (What could be/ theoretically possible) Innovation (Competitive Advantage) Commercialization 25

26 SCORED REVIEW CRITERIA Significance Does the product address an important problem, and have commercial potential? Is there a market pull for the proposed product? Approach Are design and methods well-developed and appropriate? Are problem areas addressed? Are potential pitfalls and alternative approaches provided? Innovation How novel is the technology/product and the approaches proposed to test its feasibility? Investigator Environment Are the investigators, collaborators and consultants appropriately trained and capable of completing all project tasks? Does the scientific environment contribute to the probability of success? Facilities? Independence? Commercialization Is the company s business strategy one that has a high potential for success? 26

27 START EARLY Strong proposals take time to develop! Carefully read the funding solicitation, and allow time to address all of the key requirements Assemble a strong scientific team Gain access to equipment and other resources Obtain letters of support from collaborators Complete the necessary administrative registrations Start this at least 2 months before deadline! > see info on Electronic Submission See SF424 application guide (grants.gov, era Commons) 27

28 BUILD THE RIGHT TEAM Select a Principal Investigator (PI) with the right expertise For multidisciplinary projects, consider a multi-pi team Are multiple PIs needed to cover the necessary expertise? Must appoint Contact PI (SBIR, > 50% of time w/ business) Partner to fill the gaps Academic collaborations Consultants and CROs Other companies/strategic partners Business executives who understand product development 28

29 DRAFT A CLEAR APPLICATION Specific Aims (1 page): Grab and Secure Positive Attention Focal point of the application Highlight the technology s major strengths Describe goals of the application (be specific) Include quantitative performance milestones Describe the unmet need that you are attempting to address Research Strategy Provide background information Provide detailed technical plan to achieve the Specific Aims Propose a project scope within the budget and time constraints Preliminary data not required (Ph I), but needed to be competitive Describe potential pitfalls and alternative angles of attack 29

30 CONDUCT YOUR OWN PEER REVIEW BEFORE YOU SUBMIT: Read your application as if you were a reviewer What are the weaknesses? Point out potential pitfalls (don t try to hide them); and suggest strategies to address potential problems Ask your collaborators to critically review the application Solicit feedback from independent, technically-trained readers Do they understand the proposal? Are they excited about the idea, the potential impact, and the experimental approach? 30

The reviewers are not concerned about feelings.

31 Be prepared to resubmit Competitive Program! FY15 NCI SBIR Phase I Success Rate was 10% SBIR is a tough route, and people should be aware of that. The reviewers are not concerned about feelings. But take the criticism seriously, correct the things that need correcting and be prepared to resubmit. Don t give up because of a depressing review. Mary Potasek, Ph.D. President and Co-founder Simphotek 31

NIH-Managed NCI-Managed NIH and NCI Assistance Non-Federal Funds SBIR Ph I SBIR Ph II NCISBIR Ph IIB Bridge SBIR Ph III CROSSING THE VALLEY OF DEATH Discovery Proof of Concept Product Design Product

32 NIH-Managed NCI-Managed NIH and NCI Assistance Non-Federal Funds SBIR Ph I SBIR Ph II NCISBIR Ph IIB Bridge SBIR Ph III CROSSING THE VALLEY OF DEATH Discovery Proof of Concept Product Design Product Development Manufacturing/ Delivery NCI Resources for Commercialization Workshops Application Assistance Program NCI Peer Learning and Networking Webinar I-Corps at NIH NCI Investor Initiatives Targeted NCI Workshops (e.g. the 2016 NCI SBIR Workshop to facilitate the Development of Molecularly Targeted Radiotherapy) Niche Assessment Program Commercialization Assistance Program (CAP) 32

Translational Resources (TRECS) WORKSHOP Workshop on Translational Resources to Enhance Commercialization Success Bringing together NCI

$gov/programseducation/fracworkshop Speakers from FDA, CMS, USPTO, and across NIH Panels on other sources of federal funding, resources &$

33 Translational Resources (TRECS) WORKSHOP Workshop on Translational Resources to Enhance Commercialization Success Bringing together NCI SBIR/STTR awardees to move funded technologies from bench to bedside Speakers from FDA, CMS, USPTO, and across NIH Panels on other sources of federal funding, resources & collaborative programs at NIH, and unique life science investment organizations Over 300 One-on-one meetings with program directors and speakers Brainstorm sessions with other SBIR peers and NIH staff. 33

34 Two pilot programs Peer Learning and Networking Webinar Series Goal is to improve peer learning and & provide more networking opportunities. 2-4 presenting companies share their experience and expertise and discuss potential areas of collaborations 2-4 webinar per year, next one on setting up a successful team Application Assistance Program For New or Previously Unawarded Small Businesses. Application deadline is Jan 15 for April Submission date Provide support for preparing a Phase I SBIR or STTR application, submission process and appropriate market research Specific interest in assisting SB that are owned or operated by individuals who are underrepresented in the biomedical sciences 34

35 GRANTEE RESOURCES COURSE FORMAT Curriculum tailored to life sciences Entrepreneurship program for SBIR awardees sbir.cancer.gov/icorps 3-Day Kick-off Event 6 Weekly web classes 2-Day Lessons Learned THERAPEUTICS TRACK THERAPEUTICS Expert DIAGNOSTIC TOOLS TRACK DIAGNOSTICS & ehealth Expert MEDICAL DEVICES TRACK MEDICAL DEVICE Expert I-Corps Node Instructor I-Corps Node Instructor I-Corps Node Instructor 35

36 Investor Initiatives Exclusive opportunity for some of our most promising NCI-funded companies to showcase their technologies If selected, companies Receive coaching on presentation & pitching Get chances to present at top conferences (e.g. BIO, RESI, AdvaMed, & many more!) Even if not selected, companies Can receive expert review of call-for-investment language May develop connection with investors who are interested in the field 36

37 INVESTOR INITIATIVES SHOWCASE MEETINGS EVENTS COMPANIES 300+ WITH INVESTORS & STRATEGIC PARTNERS Investor Initiatives helped us progress BIO BIO Network BIO Investor Forum AdvaMed RESI NCI SBIR s assistance was mostly to extremely valuable 91% toward our goals Life Sciences Summit 83% PMWC 37

38 Stay in Touch!

39 THANK bitly.com/ncisbirfeedback 39

NCI SBIR & STTR Seeding the Development of New Technologies To Meet the Needs of Cancer Patients

NCI SBIR & STTR Seeding the Development of New Technologies To Meet the Needs of Cancer Patients Todd Haim, PhD Program Director National Cancer Institute SBIR Development Center NIH = 27 Institutes &